Self-Reported Quality of Life and Symptom Burden in Ambulatory Patients With Multiple Myeloma on Disease-Modifying Treatment
| Autor: | Fiona Kiely, Alison Cran, Deirdre Finnerty, Tony O'Brien |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Male
medicine.medical_specialty Cross-sectional study Health Status Population Disease 03 medical and health sciences 0302 clinical medicine Quality of life Surveys and Questionnaires Internal medicine Dental Anxiety medicine Humans education Depression (differential diagnoses) Multiple myeloma Aged Aged 80 and over education.field_of_study Hematology Depression business.industry General Medicine Middle Aged medicine.disease Cross-Sectional Studies 030220 oncology & carcinogenesis Ambulatory Quality of Life Physical therapy Female Self Report Multiple Myeloma business 030215 immunology |
| Zdroj: | American Journal of Hospice and Palliative Medicine®. 34:671-676 |
| ISSN: | 1938-2715 1049-9091 |
| Popis: | Background: Knowledge of health-related quality of life (QoL) of patients with multiple myeloma on disease-modifying treatments is limited. Aim: (1) Determine symptom prevalence in patients with multiple myeloma on disease-modifying treatment. Identify the range and nature of these symptoms within the dimensions of physical, psychological, social, and financial well-being. (2) Measure self-reported QoL. (3) Compare the above-mentioned parameters to the general population and patients with advanced cancer. Method: Adults with multiple myeloma on disease-modifying treatment, attending the hematology day unit in a tertiary referral center from November 2012 to January 2013, were eligible for inclusion in a cross-sectional quantitative survey. Consenting patients completed 2 validated questionnaires, the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) supplemented by the myeloma-specific module (EORTC QLQ-MY20) and the Hospital Anxiety Depression Score (HADS). Results: Forty-one patients were included for analysis: 59% were male and 41% were female. Mean age was 63.7 years (range 46-86, standard deviation 11.24). The QoL scores were significantly lower than the general population and comparable to those with advanced cancer. The most commonly reported physical symptoms were pain (66%), fatigue (63%), and dyspnea (51%). About 54% of the patients were burdened by financial worries. Anxiety (30%) and depression (37%) were prevalent. Conclusion: Patients with myeloma on disease-modifying treatment have a lower QoL than the general population and are symptomatic across physical, psychological, financial, and social domains. A holistic approach to patient care is warranted, and patients may benefit from specialist palliative care input. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|